Business Wire

Truffle Capital and tecknowlogy Group Unveil the Results of the 15th "Truffle 100" Ranking

Share

On the face of it, the "Truffle 100" 2020 has drawn the curtain on a decade of continuous growth, which has been abruptly halted by the Covid-19 pandemic:

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200626005086/en/

  • Several records were set in 2019: cumulative turnover for the sector was €10.8bn, total workforce in the sector stood at 157,000 jobs including 25,000 in R&D. Profitability at 11.1 % is very close to its historical high of 2006-2007. Moreover, buybacks and stock market transactions were sharply higher.

Despite the fact that the solid foundations built over the last decade will be exposed to a brutal shock in 2020, the Truffle 100 clearly shows that the areas in which software publishers have invested the most extensively are those that will be the most vital to withstand the current crisis and support the economic recovery:

  • Thanks to their profit margins, which have returned to previous levels, software publishers have been able to ensure continuous research in crucial areas (in particular, the Cloud and artificial intelligence, which are the two major market trends) to support the transition to teleworking in the economy of tomorrow.

While 62% of software publishers forecast a downturn in 2020, 94% expect a return to growth in 2021.

Commenting on the 15th edition of the "Truffle 100", Bernard-Louis Roques, General Manager and Co-founder of Truffle, declared: "Software is a digital business and software publishers have been among the quickest to adapt to the crisis. In just a few months, Covid-19 brought about a forced acceleration in terms of the company's digital transition, with an irreversible digitalization of uses and organizations. Publishers will play a vital role in the development of the "post-Covid world". Finally, I would like to thank Cédric Ô, the French Secretary of State for the Digital Economy, for agreeing to sponsor the 15th edition of the "Truffle 100", which is more than a just an overview of the past, it is a leading indicator of the future."

Xavier Negiar, Chairman of the consulting and analysis firm teknowlogy Group which carried out the study and analysis, added:

"As grey as this picture may be, there has been a major trend in this software market to prepare for the end of the crisis. Now is the time to develop programs that are capable of reviving the market. And to achieve this, surely the best approach is to help companies find their own way out of this crisis."

Cédric Ô, the French Secretary of State for the Digital Economy concluded:

"Software publishers are at the core of all these changes taking place in our societies. They act as stakeholders as well as sentinels and open up new pathways for improvement for the companies they support, the employees who use their solutions and for each and every citizen, which result in significant transformations to life and work. It is this key role that explains the economic strength and resilience of this strategic sector, which is central to France's entrepreneurial fabric and excellence.

The 15th edition of the "Truffle 100", as well as the previous editions, can be viewed on the following website: https://www.truffle100.fr/

About Truffle Capital

Founded in 2001, Truffle Capital is an independent European venture capital company, specializing in life sciences (BioTech and MedTech) and breakthrough technologies in the IT sectors (FinTech and InsurTech). Truffle Capital’s mission is to support the creation and development of young innovative companies capable of becoming tomorrow’s leaders. The company is chaired by Patrick Kron and managed by Dr Philippe Pouletty and Bernard-Louis Roques, co-founders and General Managers. Since its creation, Truffle Capital has raised nearly €1.1 billion and has supported over 70 companies in the digital technology and life sciences sectors. In 2019, Truffle Capital announced it had raised nearly €400 million in new institutional funds.

About teknowlogy Group

For more than 45 years, PAC and CXP have been providing visionary and meticulous support, helping stakeholders to grow and adapt in what has become today's IT ecosystem, as well as assisting companies seeking to accelerate their digitalization process. PAC's M&A teams serve the investment fund community both with regard to acquisitions and in the analysis of the coherence of the BP (Business Plan) of their holdings in view of market trends. PAC's teams of analysts also advise ESNs, software publishers and IT service providers in terms of deciphering technological needs to enable them to adapt their strategy to offer solutions and services, owing to their oversight of European and international markets. Thanks to SITSI®, its international platform for real-time monitoring, PAC maintains an up-to-date vision of technologies and markets, and provides its customers with strategic analyses and solution benchmarks for a 360° outlook of the IT market. CXP's Project Consulting teams support TIEs and SMEs in drafting specifications, identifying IT service providers, selecting and implementing solutions adapted to their digital transformation challenges. Thanks to the MyTeknow site - CXP's platform - users now have access to a real-time monitoring of the IT services on offer in France to TIEs and SMEs.

More information: www.truffle.com — Twitter: @trufflecapital

The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.

Contact information

Maud Lazare | maud@truffle.com
DGM Conseil | +33 1 40 70 11 89

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Takeda Presents New Data Highlighting Scientific Advancements in Lung Cancer at ESMO Virtual Congress18.9.2020 13:55:00 EESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the company is presenting data from its lung cancer portfolio at the virtual European Society for Medical Oncology (ESMO) conference. Notably, insights from sub-analyses of the Phase 3 ALTA 1L study reinforce both the compelling evidence of intracranial efficacy with ALUNBRIG® (brigatinib) as a first-line treatment for patients with anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) as well as associated quality of life (QoL) data. Takeda is also featuring updated 10-month follow-up results from the Phase 1/2 trial of mobocertinib (TAK-788), demonstrating mobocertinib achieved a duration of response (DoR) of more than one year in the trial’s study population of patients with epidermal growth factor receptor (EGFR) Exon20 insertion+ metastatic NSCLC (mNSCLC). “We’re pleased to present our ongoing research in lung cancer at this year’s virtual ESMO congress, including new

Incyte Announces Encouraging Results From Phase 2 Trial of Retifanlimab (INCMGA0012) in Patients With Previously Treated, Advanced Squamous Cell Carcinoma of the Anal Canal18.9.2020 13:00:00 EESTPress release

Incyte (Nasdaq:INCY) today announced results from its Phase 2 POD1UM-202 trial evaluating retifanlimab, a PD-1 inhibitor, in previously treated patients with advanced squamous cell carcinoma of the anal canal (SCAC) who have progressed following standard platinum-based chemotherapy. The trial enrolled 94 patients, including those with well-controlled human immunodeficiency virus (HIV) infection (10%). Retifanlimab monotherapy resulted in a confirmed objective response rate (ORR) of 14% as determined by independent central review (ICR) using RECIST v1.1. Responses were observed regardless of PD-L1 status, presence of liver metastases, age or HIV+ status. Retifanlimab was generally well-tolerated with a safety profile as expected of a PD-1 inhibitor and no loss of HIV infection control. Key findings from POD1UM-202: N=94 ORR* (95% CI) 13.8% (7.6-22.5) Best OR*, n 1 CR 12 PR 33 SD DCR 48.9% DOR, median (95% CI), months 9.5 (5.6-NE) PFS, median (95% CI), months 2.3 (1.9-3.6) OS, median (95

Sigfox and Cube Infrastructure Managers Announce Major Partnership in IoT Infrastructure18.9.2020 10:30:00 EESTPress release

Sigfox, the global 0G network1 and cloud provider for industrial data, is proud to announce a new strategic alliance with Cube Infrastructure Managers (Cube), through the sale of its German 0G network to Cube. Sigfox has grown its 0G IoT services by rolling out 0G networks across 72 countries and regions, which was largely achieved with partners called Sigfox Operators. These operators are the owners of the 0G networks, which they operate as exclusive connectivity providers of Sigfox IoT services, offering worldwide connectivity to customers. The sale of the German network to Cube will allow Sigfox to finance its continued innovation efforts in data value extraction and improvements in cloud algorithms to reduce energy consumption and allow the implementation of even more cost-effective devices and sensors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200918005116/en/ Cube Infrastructure Managers, the European infrastructu

Sensorion successfully raises approximately €31 (US$ 36.5) million in an oversubscribed private placement to US and European investors18.9.2020 09:00:00 EESTPress release

Regulatory News: Not for release, publication or distribution, directly or indirectly, in or into the United States, Canada, Australia or Japan. This press release is not intended as an offer and is for informational purpose only Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN – the “Company”) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders announces today the success of its previously announced capital increase. The Company has placed 18,236,000 new ordinary shares with a nominal value of €0.10 each (the “New Shares”), for total gross proceeds of approximately € 31 million by means of an accelerated bookbuild offering to the benefit of categories of persons (the “Reserved Offering”). The issue price of the New Shares is €1.70 per share, representing a 3.5% discount to the weighted average share price on the day preceding the date on which the issuance price

ESMO 2020: Phase II CLARINET FORTE Results Show Increasing Dose Frequencies of Somatuline® Autogel® (lanreotide) Allows Patients with NETs to Delay Treatment Escalation by up to 8.3 Months18.9.2020 08:00:00 EESTPress release

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced the release of first efficacy and safety data from the CLARINET FORTE study, with the abstract to be presented as a mini-oral presentation at the 2020 European Society for Medical Oncology (ESMO) Congress, taking place virtually from 19-21 September 2020. The prospective single-arm, open-label, exploratory, international Phase II study investigated the efficacy and safety of increasing the dose frequency of Somatuline® Autogel ® (lanreotide) in patients with pancreatic or midgut NETs with centrally-assessed progression within the last two years while on a standard lanreotide regimen for ≥24 weeks. An extension of progression-free survival (PFS) rates and encouraging disease-control rates (DCR) were recorded in both tumor types, with no new safety signals. “These results support a clinically meaningful benefit to a population of patients with high unmet medical need by potentially delaying escalation to more toxic treatm

Vifor Pharma Group Announces Successful Sale of OM Pharma18.9.2020 08:00:00 EESTPress release

Regulatory News: Vifor Pharma has today announced the successful sale of 100% of the share capital of OM Pharma, a Vifor Pharma Group company to Optimus Holding Ltd. The terms of the deal include: A purchase consideration of MCHF 435 for 100% of the share capital An earn out related to potential future value gains on 20% of Optimus Holding Ltd. equity to be determined before the end of 2027 upon a trade sale, IPO or EBITDA multiple This earn out together with the purchase consideration could result in a total transaction value exceeding MCHF 500. The deal is expected to close within 30 days. OM Pharma is a Geneva-based company mainly active in the field of microbial derived immunotherapeutics and has developed strongly outside the core strategy of Vifor Pharma over the past few years. Optimus Holding Ltd. is a Swiss Group, founded by Etienne Jornod together with long-standing Swiss entrepreneurs and Abdi Ibrahim (28.5%), a Turkey-based pharmaceutical company operating in 12 countries a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom